Racura Oncology is a clinical-stage biotech developing RC220 (bisantrene), a potential treatment for cancers such as AML and lung cancer. The company is pre-revenue and mainly funded through cash reserves and capital raises while advancing clinical trials. Its future valuation depends largely on trial results, regulatory progress and potential partnerships if the drug proves effective.
4DMedical Limited is an Australian medtech company developing lung imaging software that turns standard scans into functional insights. It has strong growth potential through scalable products like CT:VQ, but remains speculative due to ongoing cash burn, reliance on adoption, and funding risk.
Invictus Energy is an early-stage oil and gas explorer in Zimbabwe with large but unproven resource potential. With no revenue and heavy funding needs, the stock offers significant upside if discoveries succeed, but remains a high-risk, news-driven investment.
Encounter Resources (ASX: ENR) is an Australian mineral explorer targeting copper and critical minerals. Backed by solid funding and major partnerships, its share price exhibits bullish reversal signs, though future growth relies heavily on successful high-grade exploration discoveries.
Dateline Resources (ASX: DTR) is advancing its California-based gold and rare earth projects while navigating funding, dilution, and execution risks. Technically, the stock is testing major long-term support near 0.16, with RSI conditions suggesting a possible stabilisation phase if buying interest returns.
Hawk Resources is an early-stage explorer targeting high-grade copper-gold in Utah and lithium in Brazil, with emerging exposure to rare earths. Recent trading was driven by its Olympus scandium deal, a A$5.87A$5.87 million raising, and renewed momentum at Cactus.
...
